Fatal NAD+ infusion highlights risks in unregulated longevity market
The death of a New York woman following an unlicensed intravenous NAD⁺ infusion has underscored the growing commercial and regulatory risks in the booming but scientifically unproven longevity medicine sector.
Elizabeth Baron, a 27-year-old woman from New York City, died this week after receiving an intravenous NAD⁺ infusion at the Bereshit Lifestyle Center. Luis Rojas Cabrera, the 55-year-old clinic owner, was charged with reckless endangerment and unauthorized practice of a profession. Cabrera claims medical training from the Dominican Republic but holds no license to practice in the United States.
The incident highlights a growing vulnerability in the commercial longevity sector. NAD⁺ is a coenzyme central to energy production and DNA repair that naturally declines with age. Because the molecule is rapidly metabolized, most serious human research focuses on oral precursors like NR and NMN, which have shown promise in animal models. Direct intravenous NAD⁺ infusions, however, have become a lucrative wellness fad despite lacking rigorous human clinical evidence.
This gap between intense consumer demand and slow scientific progress is creating a fragmented market. Legitimate businesses in the nascent longevity medicine space face significant reputational and regulatory risks from unlicensed operators. Cabrera’s clinic, for example, marketed a "personalized Wellness Kit with the combination of over 100 components" alongside bombastic scientific claims, with no evidence such mixtures were tested for safety or interactions.
The problem is not isolated. Last year at RAADfest, a longevity enthusiast gathering, two people nearly died after receiving injections of unlicensed peptides from improperly credentialed practitioners. Such events threaten to undermine an entire industry that is struggling to establish clinical credibility.
“Stories like this are heartbreaking,” said Dr. Matt Kaeberlein, a longevity researcher at the University of Washington. “Unfortunately, it isn’t the first time someone has been seriously harmed – or killed – while pursuing an unproven ‘longevity’ therapy. The broader lesson is one I’ve been repeating for years: every experimental intervention comes with unknown risks.”
Industry leaders argue the solution lies in stricter international governance rather than abandoning the field. “Healthy Longevity Medicine is a medical discipline and, like every other medical discipline, it must be grounded in evidence, clinical governance, and patient safety,” said Dr. Andrea Maier, a longevity medicine pioneer. Dr. Evelyne Bischof, President of the Healthy Longevity Medicine Society, added that substances produced without rigorous independent quality control or verification by accredited laboratories carry profound safety concerns that regulators can no longer afford to ignore.
